NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2017 (“Q1 FY 2018”).
Q1 FY 2018 Highlights
- Net revenue increased 15.1% to $6.4 million from $5.5 million during the three months ended September 30, 2016 (“Q1 FY 2017”).
- Gross profit rose 14.1% to $4.9 million from $4.3 million in Q1 FY 2017.
- Operating income declined to $162,000, from $289,000 in Q1 FY 2017, primarily due to higher selling, general and administrative (“SG&A) expenses in support of revenue growth initiatives.
- Net income equaled $121,000, or $0.01 per diluted share, compared to $191,000, or $0.02 per diluted share, in Q1 FY 2017.
- Field sales employees grew to 41 at the end of Q1 FY 2018 from 31 at the end of Q1 FY 2017.
Kathleen Skarvan, President and Chief Executive Officer of Electromed, commented, “We achieved strong top-line growth in the first quarter of fiscal 2018, driven by a 16.5% year-over-year increase in home care revenue, and remained profitable despite a higher level of investment in the business. This quarter we executed on our growth strategies and continued to increase investment in our sales and reimbursement teams with a focus on adult pulmonology, calling attention to evidence-based studies that differentiate SmartVest® and gaining traction in the deployment of SmartVest Connect™, our innovative wireless connectivity and patient monitoring solution. We also have strengthened our senior leadership team. Last month, we were excited to announce the appointment of Kathryn Thompson, an accomplished healthcare industry veteran, as Vice President of Reimbursement. Kathryn will lead Electromed’s preeminent reimbursement and customer care team, supporting referring clinics and patients who use the SmartVest Airway Clearance System.”
Ms. Skarvan continued, “This month we will commence shipping of SmartVest Connect to targeted, strategic adult pulmonology clinics throughout the United States based on positive feedback from patients and clinicians in the pediatric and cystic fibrosis markets. We expect the number of adult clinics involved to grow steadily as clinicians recognize the value of using wireless monitoring together with SmartVest to improve therapy adherence and quality of life for patients with compromised pulmonary function. All in all, our organic growth strategy is tracking on plan and we expect a higher level of investment in the business to deliver enhanced revenue growth beginning in the second half of fiscal 2018.”
Q1 FY 2018 Review
Net revenue increased 15.1% to $6.4 million in Q1 FY 2018 from $5.5 million in Q1 FY 2017, driven by higher home care revenue. Home care revenue rose 16.5% to $6.0 million in Q1 FY 2018 from $5.1 million in Q1 FY 2017. This increase was primarily due to an increase in approvals and referrals, driven by a higher number of field sales employees.
Gross profit increased 14.1% to $4.9 million, or 77.4% of net revenue, in Q1 FY 2018 from $4.3 million, or 78.0% of net revenue, in Q1 FY 2017. The increase in gross profit resulted primarily from an increase in home care revenue.
Operating expenses, which include SG&A as well as research and development (“R&D”) expenses, totaled $4.8 million, or 74.8% of net revenue, in Q1 FY 2018 compared with $4.0 million, or 72.8% of net revenue, in the same period of the prior year. SG&A expenses increased 27.5% to $4.7 million in Q1 FY 2018 from $3.7 million in Q1 FY 2017, primarily due to higher payroll and compensation-related expenses, higher professional fees, increased recruiting fees driven by expansion of our sales employees and increased travel, meals and entertainment expenses. R&D expenses totaled $71,000 in Q1 FY 2018 compared to $351,000 in Q1 FY 2017.
Operating income decreased to $162,000 in Q1 FY 2018, from $289,000 in Q1 FY 2017, primarily due to higher SG&A expense. The higher level of SG&A expense in Q1 FY 2018 is consistent with the Company’s strategy to increase its investment in revenue growth initiatives.
Net income before income tax expense totaled $158,000 in Q1 FY 2018, compared to $272,000 in Q1 FY 2017.
Net income equaled $121,000, or $0.01 per diluted share, in Q1 FY 2018, compared to $191,000, or $0.02 per diluted share, in Q1 FY 2017. In Q1 FY 2018, income tax expense totaled $37,000, compared to $81,000 in the same period of the prior year.
Electromed’s balance sheet at September 30, 2017 included cash of $5.8 million, long-term debt including current maturities of $1.1 million, working capital of $15.9 million, and shareholders’ equity of $19.4 million.
Management will host a conference call on November 8, 2017 at 8:00 am CT (9:00 am ET) to discuss Q1 FY 2018 financial results and other matters.
Interested parties may participate in the call by dialing:
- (877) 407-9753 (Domestic)
- (201) 493-6739 (International)
The conference call will also be accessible via the following link:
For those who cannot listen to the live broadcast, an online webcast replay will be available in the Investor Relations section of Electromed’s web site at: http://www.smartvest.com/electromed/investor-relations/.
About Electromed, Inc.
Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. The Company is headquartered in New Prague, Minnesota and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.
Certain statements in this release constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect current views with respect to future events and financial performance and include any statement that does not directly relate to a current or historical fact. Forward-looking statements can generally be identified by the words “anticipate,” “believe,” “estimate,” “expect,” “will” and similar words. Forward-looking statements in this release include estimated revenue trends, changes in sales opportunities and our sales force, product and service innovations, referral quality and processing, financial performance, profitability and market trends. Forward-looking statements cannot be guaranteed and actual results may vary materially due to the uncertainties and risks, known and unknown, associated with such statements. Examples of risks and uncertainties for the Company include, but are not limited to, the impact of emerging and existing competitors, the effect of new legislation on the Company’s industry and business, the effectiveness of the Company’s sales and marketing and cost control initiatives, changes to reimbursement programs, as well as other factors described from time to time in the Company’s reports to the Securities and Exchange Commission (including the Company’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent reports on Form 10-Q and Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all of the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this release.
Financial Tables Follow:
Condensed Balance Sheets
|September 30, 2017||June 30, 2017|
|Accounts receivable (net of allowances for doubtful accounts of $45,000)||9,644,132||9,949,759|
|Prepaid expenses and other current assets||565,878||393,319|
|Income tax receivable||226,582||-|
|Total current assets||18,677,737||18,476,272|
|Property and equipment, net||3,262,474||3,303,233|
|Finite-life intangible assets, net||700,454||721,276|
|Deferred income taxes||467,000||460,000|
|Liabilities and Shareholders’ Equity|
|Current maturities of long-term debt||$||51,207||$||50,703|
|Income taxes payable||-||156,524|
|Other accrued liabilities||536,423||438,748|
|Total current liabilities||2,741,595||2,895,974|
|Long-term debt, less current maturities and net of debt issuance costs||1,085,203||1,097,125|
|Commitments and Contingencies|
Common stock, $0.01 par value; authorized: 13,000,000 shares;
|Additional paid-in capital||14,218,687||14,028,602|
|Total shareholders’ equity||19,379,055||19,067,550|
|Total liabilities and shareholders’ equity||$||23,205,853||$||23,060,649|
Condensed Statements of Operations
For the Three Months Ended
|Cost of revenues||1,445,284||1,217,736|
|Selling, general and administrative||4,703,592||3,687,908|
|Research and development||70,583||350,840|
|Total operating expenses||4,774,175||4,038,748|
|Interest expense, net of interest income of $9,630 and $3,366, respectively||4,199||16,707|
|Net income before income taxes||158,120||272,172|
|Income tax expense||37,000||81,000|
|Income per share:|
|Weighted-average common shares outstanding:|
Condensed Statements of Cash Flows
Three Months Ended
|Cash Flows From Operating Activities|
|Adjustments to reconcile net income to net cash provided (used) by operating activities:|
|Amortization of finite-life intangible assets||28,258||30,674|
|Amortization of debt issuance costs||2,197||4,344|
|Share-based compensation expense||190,385||109,208|
|Deferred income taxes||(7,000)||-|
|Changes in operating assets and liabilities:|
|Prepaid expenses and other assets||(172,097)||(12,500)|
|Income tax receivable||(226,582)||58,289|
|Income tax payable||(156,524)||-|
|Accounts payable and accrued liabilities||(36,915)||(1,220,113)|
|Net cash provided (used) by operating activities||328,127||(1,215,869)|
|Cash Flows From Investing Activities|
|Expenditures for property and equipment||(95,011)||(49,462)|
|Expenditures for finite-life intangible assets||(7,436)||(21,494)|
|Net cash used in investing activities||(102,447)||(70,956)|
|Cash Flows From Financing Activities|
|Principal payments on long-term debt including capital lease obligations||(12,397)||(12,518)|
|Net increase (decrease) in cash||213,283||(1,299,343)|
|Beginning of period||5,573,709||5,123,355|
|End of period||$||5,786,992||$||3,824,012|